A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology. Based on data from an Alliance for Clinical Trials in Oncology study, this finding could lead to more personalized treatments and better outcomes for patients.

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained. However, a cure ― completely ridding the body of the virus — has only been documented in a handful of patients who underwent complex and high-risk bone marrow transplants for life-threatening blood cancers such as leukemia or lymphoma.

UTHealth Houston, in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health), has been awarded $50 million from the Texas Health and Human Services Commission to lead a collaborative two-year, multicenter research trial that will evaluate the effect of ibogaine on patients suffering from addiction, traumatic brain injury, and other behavioral health conditions.

The Universidad Carlos III de Madrid (UC3M) inaugurated today its Scientific Computing Center (C3), a new state-of-the-art supercomputing facility designed to support R&D&I projects with high demands in computation, storage and data processing. This supercomputer, ranked 81st worldwide according to the IO500 ranking, reinforces the University’s commitment to scientific and technological excellence and will be available to the UC3M research community, other research centers, and interested companies. The C3 will represent a major advance in socially impactful research in fields such as aeronautics, biology, and health sciences, among others.

Cancer researchers at the University of Tennessee Health Science Center have published three groundbreaking studies demonstrating how advanced artificial intelligence and population health analytics can identify and address barriers to quality cancer care.

The bacterial pathogen Bartonella bacilliformis causes in South America one of the most dangerous infectious diseases known: the so-called “Oroya fever.” Without antibiotic treatment, 90 percent of the infected patients will die, as the pathogen destroys red blood cells. Researchers at University Medicine Frankfurt have now clarified how the pathogen triggers this hemolytic disease. In laboratory experiments, they were even able to inhibit the destruction of red blood cells. The results open up a possible avenue for developing a novel therapy against this often fatal infectious disease.